The incretin system in type 2 diabetes mellitus: cardiovascular effects

Abstract

Cardiovascular diseases are the commonest cause of high mortality rate among the patients with type 2 diabetes mellitus. (DM2). The safety of hypoglycemic agents considered as potential risk factors of cardiovascular pathology becomes an increasingly important concern in the choice of the strategy for the treatment of DM2 as recommended in the relevant domestic and international guidelines. The data of multifaceted action exerted by incretins on the cardiovascular system have recently become available. The potential cardioprotective properties of incretin-based pharmaceutical products and mechanisms of their action are discussed